Clofutriben

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is an emerging, privately-held biotech focused on addressing the underlying role of cortisol excess in cardiometabolic diseases. Its core technology is the inhibition of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) to lower pathogenic intracellular cortisol levels in key metabolic tissues. The company is advancing its lead oral candidate, clofutriben, in a Phase 2b trial for type 2 diabetes with elevated cortisol, a prevalent subpopulation with high unmet need. Backed by a recent $95 million Series B financing, Sparrow is positioned to generate critical clinical proof-of-concept data for its novel therapeutic approach.

Therapeutic Areas